Overview

Pharmacovigilance Market is poised to value over CAGR of over 11.5% during the forecast period 2022 to 2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Pharmacovigilance Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Pharmacovigilance Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Pharmacovigilance Market:
• Accenture
• Clinquest Group B.V.
• IQVIA
• Cognizant
• Laboratory Corporation of America Holdings
• IBM Corporation
• ArisGlobal
• ICON Plc.
• Capgemini
• ITClinical
• TAKE Solutions
• PAREXEL International Corporation
• BioClinica, Inc.
• Wipro Limited
• UNITED BIOSOURCE CORPORATION
• FMD K&L
(Note: The list of the major players will be updated with the latest market scenario and trends)

Pharmacovigilance Market Segmentation:

By Service Provider
• In-house
• Contract Outsourcing

By Product Life Cycle 
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

By Type 
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

By Process Flow 
• Case Data Management
  o Case Logging
  o Case Data Analysis
  o Medical Reviewing & Reporting
• Signal Detection
  o Adverse Event Logging
  o Adverse Event Analysis
  o Adverse Event Review & Reporting
• Risk Management System
  o Risk Evaluation System
  o Risk Mitigation System

By Therapeutic Area
• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

By End-Users
• Pharmaceuticals
• Biotechnology Companies
• Medical Device Manufacturers
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Pharmacovigilance Market By Service Provider, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Users and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Product Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
                2.1.1.1. Key Data from Secondary Sources
         2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Global Pharmacovigilance Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Pharmacovigilance Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Pharmacovigilance Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Pharmacovigilance Market, By Service Provider Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. In-house
   7.2. Contract Outsourcing

8. Global Pharmacovigilance Market, By Product Life Cycle Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Pre-clinical
   8.2. Phase I
   8.3. Phase II
   8.4. Phase III
   8.5. Phase IV

9. Global Pharmacovigilance Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Spontaneous Reporting
   9.2. Intensified ADR Reporting
   9.3. Targeted Spontaneous Reporting
   9.4. Cohort Event Monitoring
   9.5. EHR Mining

10.Global Pharmacovigilance Market, By Process Flow Historical Analysis and Forecast 2022-2028 (USD Million)  
   10.1. Case Data Management
         10.1.1. Case Logging
         10.1.2. Case Data Analysis
         10.1.3. Medical Reviewing & Reporting
   10.2. Signal Detection
         10.2.1. Adverse Event Logging
         10.2.2. Adverse Event Analysis
         10.2.3. Adverse Event Review & Reporting
   10.3. Risk Management System
         10.3.1. Risk Evaluation System
         10.3.2. Risk Mitigation System
  
11. Global Pharmacovigilance Market, By Therapeutic Area Historical Analysis and Forecast 2022-2028 (USD Million)  
    11.1. Oncology
    11.2. Neurology
    11.3. Cardiology
    11.4. Respiratory Systems
    11.5. Others

12. Global Pharmacovigilance Market, By End-Users Historical Analysis and Forecast 2022-2028 (USD Million)  
    12.1. Pharmaceuticals
    12.2. Biotechnology Companies
    12.3. Medical Device Manufacturers
    12.4. Others

13. North America Pharmacovigilance Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. U.S.A
          13.2.2. Canada
          13.2.3. Mexico
    13.3. Market Size (USD Million) Forecast for North America 2022-2028

14. Latin America Pharmacovigilance Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Brazil
          14.2.2. Venezuela
          14.2.3. Argentina
          14.2.4. Rest of Latin America
    14.3. Market Size (USD Million) Forecast for Latin America 2022-2028

15. Europe Pharmacovigilance Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. Germany
          15.2.2. U.K         
          15.2.3. France
          15.2.4. Italy
          15.2.5. Spain
          15.2.6. Russia
          15.2.7. Poland
          15.2.8. Rest of Europe
    15.3. Market Size (USD Million) Forecast for Europe 2022-2028

16. Asia Pacific Pharmacovigilance Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    16.1. Introduction
    16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          16.2.1. Japan
          16.2.2. China
          16.2.3. India
          16.2.4. Australia and New Zealand
          16.2.5. ASEAN
          16.2.6. Rest of Asia Pacific
    16.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

17. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    17.1. Introduction
    17.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          17.2.1. GCC
          17.2.2. Israel
          17.2.3. South Africa
          17.2.4. Rest of MEA
    17.3. Market Size (USD Million) Forecast for MEA 2022-2028

18. Market Share Analysis and Competitive Landscape   
    18.1. Global Landscape - Key Players, Revenue and Presence
    18.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    18.3. Global Emerging Companies
    18.4. North America - Market Share Analysis and Key Regional Players
    18.5. Europe - Market Share Analysis and Key Regional Players
    18.6. Asia Pacific - Market Share Analysis and Key Regional Players
    18.7. Global Key Player - Growth Matrix

19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    19.1. Accenture
          19.1.1. Company Overview
          19.1.2. Product Portfolio
          19.1.3. SWOT Analysis
          19.1.4. Financial Overview
          19.1.5. Strategic Overview
    19.2. Clinquest Group B.V.
          19.2.1. Company Overview
          19.2.2. Product Portfolio
          19.2.3. SWOT Analysis
          19.2.4. Financial Overview
          19.2.5. Strategic Overview 
    19.3. IQVIA
          19.3.1. Company Overview
          19.3.2. Product Portfolio
          19.3.3. SWOT Analysis
          19.3.4. Financial Overview
          19.3.5. Strategic Overview
    19.4. Cognizant
          19.4.1. Company Overview
          19.4.2. Product Portfolio
          19.4.3. SWOT Analysis
          19.4.4. Financial Overview
          19.4.5. Strategic Overview
    19.5. Laboratory Corporation of America Holdings
          19.5.1. Company Overview
          19.5.2. Product Portfolio
          19.5.3. SWOT Analysis
          19.5.4. Financial Overview
          19.5.5. Strategic Overview          
    19.6. IBM Corporation
          19.6.1. Company Overview
          19.6.2. Product Portfolio
          19.6.3. SWOT Analysis
          19.6.4. Financial Overview
          19.6.5. Strategic Overview      
    19.7. ArisGlobal
          19.7.1. Company Overview
          19.7.2. Product Portfolio
          19.7.3. SWOT Analysis
          19.7.4. Financial Overview
          19.7.5. Strategic Overview
    19.8. ICON Plc.
          19.8.1. Company Overview
          19.8.2. Product Portfolio
          19.8.3. SWOT Analysis
          19.8.4. Financial Overview
          19.8.5. Strategic Overview 
    19.9. Capgemini
          19.9.1. Company Overview
          19.9.2. Product Portfolio
          19.9.3. SWOT Analysis
          19.9.4. Financial Overview
          19.9.5. Strategic Overview 
    19.10.ITClinical 
          19.10.1. Company Overview
          19.10.2. Product Portfolio
          19.10.3. SWOT Analysis
          19.10.4. Financial Overview
          19.10.5. Strategic Overview
    19.11.TAKE Solutions 
          19.11.1. Company Overview
          19.11.2. Product Portfolio
          19.11.3. SWOT Analysis
          19.11.4. Financial Overview
          19.11.5. Strategic Overview
    19.12.PAREXEL International Corporation 
          19.12.1. Company Overview
          19.12.2. Product Portfolio
          19.12.3. SWOT Analysis
          19.12.4. Financial Overview
          19.12.5. Strategic Overview
    19.13.BioClinica, Inc. 
          19.13.1. Company Overview
          19.13.2. Product Portfolio
          19.13.3. SWOT Analysis
          19.13.4. Financial Overview
          19.13.5. Strategic Overview
    19.14.Wipro Limited 
          19.14.1. Company Overview
          19.14.2. Product Portfolio
          19.14.3. SWOT Analysis
          19.14.4. Financial Overview
          19.14.5. Strategic Overview
    19.15.UNITED BIOSOURCE CORPORATION 
          19.15.1. Company Overview
          19.15.2. Product Portfolio
          19.15.3. SWOT Analysis
          19.15.4. Financial Overview
          19.15.5. Strategic Overview
    19.16.FMD K&L 
          19.16.1. Company Overview
          19.16.2. Product Portfolio
          19.16.3. SWOT Analysis
          19.16.4. Financial Overview
          19.16.5. Strategic Overview

20. Pre and Post COVID-19 Impact
    20.1. Positive influence on the healthcare industry
    20.2. The financial disruption of the manufacturing sector
    20.3. Impact of COVID-19 on emerging companies
    20.4. Significant mandates in the healthcare regulations initiated by administrations
    20.5. The overall economic slowdown of the developing and developed nations

21. FutureWise SME Key Takeaway Points for Client

Tables

Figures